AURA
Aura Biosciences IncKey Statistics
About Aura Biosciences Inc
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its proprietary virus-like particle (VLP) technology. Its lead investigational drug, AU-011, is designed to selectively target and eradicate ocular cancer cells, minimizing damage to surrounding healthy tissue, which underscores significant advancements in precision oncology. With a robust clinical pipeline addressing critical unmet needs in cancer therapy and backed by an experienced management team, Aura is strategically positioned to make notable strides in the oncology market. The company’s collaborative partnerships further bolster its innovation potential, aligning with the increasing demand for targeted therapies in the modern healthcare ecosystem.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-117.51M |
| Operating Margin | 0.00% |
| Return on Equity | -95.60% |
| Return on Assets | -50.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.67 |
| Price-to-Book | 7.34 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -5.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $103.39M |
| Float | $93.38M |
| % Insiders | 1.01% |
| % Institutions | 51.03% |
Historical Volatility
Volatility is currently contracting